Targeting prostate cancer by new bispecific monocyte engager directed to prostate-specific membrane antigen
PLOS ONE · 2025
DOI: 10.1371/journal.pone.0307353 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, 2025. Verfasst von Gargi Das und 8 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Structural Biology, Institute of Biotechnology of the Czech Academy of Sciences, Vestec, Czech Republic. Hauptthemen laut MEDLINE: Monocytes, Antibodies, Bispecific, Glutamate Carboxypeptidase II, Antigens, Surface. Die Arbeit nennt 99 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, Akademie Věd České Republiky, Grantová Agentura, Univerzita Karlova.
Abstract (Originalsprache)
Prostate cancer (PCa) ranks as the second leading cause of cancer-related deaths among men in the United States. Prostate-specific membrane antigen (PSMA) represents a well-established biomarker of PCa, and its levels correlate positively with the disease progression, culminating at the stage of metastatic castration-resistant prostate cancer. Due to its tissue-specific expression and cell surface localization, PSMA shows superior potential for precise imaging and therapy of PCa. Antibody-based immunotherapy targeting PSMA offers the promise of selectively engaging the host immune system with minimal off-target effects. Here we report on the design, expression, purification, and characterization of a bispecific engager, termed 5D3-CP33, that efficiently recruits macrophages to the vicinity of PSMA-positive cancer cells mediating PCa death. The engager was engineered by fusing the anti-PSMA 5D3 antibody fragment to a cyclic peptide 33 (CP33), selectively binding the Fc gamma receptor I (FcγRI/CD64) on the surface of phagocytes. Functional parts of the 5D3-CP33 engager revealed a nanomolar affinity for PSMA and FcγRI/CD64 with dissociation constants of K D = 3 nM and K D = 140 nM, respectively. At a concentration as low as 0.3 nM, the engager was found to trigger the production of reactive oxygen species by U937 monocytic cells in the presence of PSMA-positive cells. Moreover, flow cytometry analysis demonstrated antibody-dependent cell-mediated phagocytosis of PSMA-positive cancer cells by U937 monocytes when exposed to 0.15 nM 5D3-CP33. Our findings illustrate that 5D3-CP33 effectively and specifically activates monocytes upon PSMA-positive target engagement, resulting in the elimination of tumor cells. The 5D3-CP33 engager can thus serve as a promising lead for developing new immunotherapy tools for the efficient treatment of PCa.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Laboratory of Structural Biology, Institute of Biotechnology of the Czech Academy of Sciences, Vestec, Czech Republic.
- Department of Cell Biology, Faculty of Science, Charles University, Prague, Czech Republic.
- Lombardi Comprehensive Cancer Center, Georgetown University, Washington, D.C., United States of America.
ORCID-Profile: Alejandro Villagra, Zora Novakova
Förderung
- NCI NIH HHS
- Akademie Věd České Republiky
- Grantová Agentura, Univerzita Karlova
- Ministerstvo Školství, Mládeže a Tělovýchovy
- National Institutes of Health
Zitieren
APA
Das, G., Ptacek, J., Campbell, J., Li, X., Havlinova, B., Noonepalle, S. K., Villagra, A., Barinka, C., & Novakova, Z. (2025). Targeting prostate cancer by new bispecific monocyte engager directed to prostate-specific membrane antigen. PLOS ONE. https://doi.org/10.1371/journal.pone.0307353
Vancouver
Das G, Ptacek J, Campbell J, Li X, Havlinova B, Noonepalle SK, et al. Targeting prostate cancer by new bispecific monocyte engager directed to prostate-specific membrane antigen. PLOS ONE. 2025. doi:10.1371/journal.pone.0307353
BibTeX
@article{Das2025,
author = {Das, Gargi and Ptacek, Jakub and Campbell, Jana and Li, Xintang and Havlinova, Barbora and Noonepalle, Satish Kumar and Villagra, Alejandro and Barinka, Cyril and Novakova, Zora},
title = {Targeting prostate cancer by new bispecific monocyte engager directed to prostate-specific membrane antigen},
journal = {PLOS ONE},
year = {2025},
doi = {10.1371/journal.pone.0307353}
}
EUVIMED